Chronic myeloid leukaemia (CML) can be considered, for some aspects, a model for malignant tumours that evolve through a multi-step pathogenetic process. In its natural history, CML is usually ...
Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid leukemia (CML), which gained clearance in ...
The use of tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) is one of the greatest single advances in the targeted treatment of cancer but, in most cases, TKI therapy suppresses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback